Medical comorbidity in schizophrenia

Schizophrenia Bulletin

Volumn 22, Issue 3, 1996, Pages 413-430

  Jeste, Dilip V ^a,b   Gladsjo, Julie Akiko ^d   Lindamer, Laurie A ^d   Lacro, Jonathan P ^a,c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANOSOGNOSIA; CANCER; COGNITIVE DEFECT; DISEASE PREDISPOSITION; HUMAN; PHYSICAL DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCHIZOPHRENIA; SENSORY DYSFUNCTION; SUBSTANCE ABUSE;

EID: 0029815216     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/22.3.413     Document Type: Review

References (119)

1. Adler, L.E.; Hoffer, L.J.; Griffith, J.; Waldo, M.C.; and Freedman, R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biological Psychiatry, 32:607-616, 1992.
2. Adler, L.E.; Hoffer, L.D.; Wiser, A.; and Freedman, R. Normalization of auditory physiology by cigarette smoking in schizophrenia patients. American Journal of Psychiatry, 150:1856-1861, 1993.
3. . Allebeck, P. Schizophrenia: A lifeshortening disease. Schizophrenia Bulletin, 15:(1)81-89, 1989.
4. Allebeck, R.; Rodvall, Y.; and Wisedt, B. Incidence of rheumatoid arthritis among patients with schizophrenia, affective psychosis, and neurosis. Acta Psychiatrica Scandinavica, 71:615-619, 1985.
5. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: The Association, 1987.
6. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994a.
7. American Psychiatric Association. Medication-induced movement disorders. In: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: The Association, 1994b. pp. 678-680.
8. Andreasen, N.C., and Olsen, S. Negative vs. positive schizophrenia: Definition and validation. Archives of General Psychiatry, 39:789-794, 1982.
9. Baldwin, J.A. Schizophrenia and physical disease, Psychological Medicine, 9:611-618, 1979.
10. Baldwin, J.A. Schizophrenia and physical disease: A preliminary analysis of the data from the Oxford Record Linkage Study. In: Hemmings, G., ed. The Biochemistry of Schizophrenia and Addiction: In Search of a Common Factor. Baltimore, MD: University Park Press, 1980. pp. 297-318.
11. Baron, J.A. Cigarette smoking and Parkinson's disease. Neurology, 36:1490-1496, 1986.
12. Beatty, W.W.; Jocic, Z.; Monson, N.; and Katzung, V.M. Problem solving by schizophrenic and schizoaffective patients on the Wisconsin and California Card Sorting Tests. Neuropsychology, 8:49-54, 1994.
13. Bilder, R.M.; Lipschutz-Broch, L.; Reiter, G.; Geisler, S.H.; Mayerhoff, D.I.; and Lieberman, J.A. Intellectual deficits in first-episode schizophrenia: Evidence for progressive deterioration. Schizophrenia Bulletin, 18(3):437-448, 1992.
14. Binder, R.L.; Kazamatsuri, H.; Nishimura, T.; and McNeil, D. Smoking and tardive dyskinesia. Biological Psychiatry, 22:1280-1282, 1987.
15. Bleuler, M. A 23-year longitudinal study of 208 schizophrenics and impressions in regard to the nature of schizophrenia. In: Rosenthal, D., and Kety, S.S., eds. The Transmission of Schizophrenia. New York, NY: Pergamon Press, 1968. pp. 3-12.
16. Bornstein, R.A.; Nasrallah, H.A.; Olson, S.C.; Coffman, J.A.; Torello, M.; and Schwarzkopf, S.B. Neuropsychological deficit in schizophrenic subtypes: Paranoid, nonparanoid, and schizoaffective subgroups. Psychiatry Research, 31:15-24, 1990.
17. Brady, K.T.; Anton, R.; Ballenger, J.C.; Lydiard, R.B.; Adinoff, B.; and Selander, J. Cocaine abuse among schizophrenic patients. American Journal of Psychiatry, 147(9):1164-1167, 1990.
18. Braff, D.L.; Heaton, R.; Kuck, J.; Cullum, M.; Moranville, J.; Grant, I.; and Zisook, S. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Archives of General Psychiatry, 48:891-898, 1991.
19. Brambilla, F.; Guastalla, A.; Guerrini, A.; Riggi, F.; Rovere, C.; Zanoboni, A.; and Zanoboni-Muciaccia, W. Glucose-insulin metabolism in chronic schizophrenia. Diseases of the Nervous System, 37:98-103, 1976.
20. Caldwell, C.B., and Gottesman, I.I. Schizophrenics kill themselves too: A review of risk factors for suicide. Schizophrenia Bulletin, 16(4):571-589, 1990.
21. Casey, D.E., and Keepers, G.A. Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia. In: Casey, D.E., and Christensen, A.V. eds. Psychopharmacology: Current Trends. Berlin, Germany: Springer-Verlag, 1988. pp. 74-93.
22. Ciompi, L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin, 6(4):606-618, 1980.
23. Cohen L.J.; Test, M.A., and Brown, R.L. Suicide and schizophrenia: Data from a prospective community treatment study. American Journal of Psychiatry, 147:602-607, 1990.
24. Cohen, M., and Klein, D.F. Drug abuse in a young psychiatric population. American Journal of Orthopsychiatry, 40:448-455, 1970.
25. Craig, T.J., and Lin, S.P. Cancer and mental illness. Comprehensive Psychiatry, 22:404-410, 1981.
26. Cuffel, B.J. Comorbid substance use disorder: Prevalence, patterns of use, and course. In: Drake, R., ed. A Dual Diagnosis of Major Mental Illness and Substance Disorder: II. Directions for Mental Health Services. San Francisco, CA: Jossey-Bass, in press.
27. Cuffel, B.J.; Shumway, M.; Chouljian, T.L.; and Macdonald, T. A longitudinal study of substance use and community violence in schizophrenia. Journal of Nervous and Mental Disease, 182:704-708, 1994.
28. Davidson, M., and Haroutunian, V. Cognitive impairment in geriatric schizophrenic patients. In: Bloom, F.E., and Kupfer, D.J., eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, 1995. pp. 1447-1549.
29. Day, S.J., and Graham, D.F. Sample size estimation for comparing two or more treatment groups in clinical trials. Statistics in Medicine, 10:33-43, 1991.
30. Dearholt, D.W., and Schvaneveldt, R.W. Properties of pathfinder networks. In: Schvaneveldt, R.W., ed. Pathfinder Associate Networks: Studies in Knowledge Organization. Norwood, NJ: Ablex, 1990. pp. 1-30.
31. de Leon, J.; Verghese, C.; Tracy, J.I.; Josiassen, R.C.; and Simpson, G.M. Polydipsia and water intoxication in psychiatric patients: A review of the epidemiological literature. Biological Psychiatry, 35:408-119, 1994.
32. Dixon, L.; Haas, G.; Weiden, P.J.; Sweeney, J.; and Frances, A.J. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. American Journal of Psychiatry, 148(2):224-230, 1991.
33. Dixon, L.; Weiden, P.J.; Haas, G.; Sweeney, J.; and Frances, A.J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Comprehensive Psychiatry, 33:121-122, 1992.
34. Drake, R.E.; Osher, F.C.; and Wallach, M. A. Alcohol use and abuse in schizophrenia: A prospective community study. Journal of Nervous and Mental Disease, 177:408-414, 1989.
35. Duke, P.J.; Pantelis, C.; and Barnes, T.R. South Westminster schizophrenia survey: Alcohol use and its relationship to symptoms, tardive dyskinesia, and illness onset. British Journal of Psychiatry, 164:630-636, 1994.
36. Dworkin, R.H. Pain insensitivity in schizophrenia: A neglected phenomenon and some implications. Schizophrenia Bulletin, 20(2):235-248, 1994.
37. Eaton, W.W.; Hayward, C.; and Ram, R. Schizophrenia and rheumatoid arthritis: A review. Schizophrenia Research, 6:181-192, 1992.
38. Folstein, M.F.; Folstein, S.E.; and McHugh, P.R. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12:189-198, 1975.
39. Ganzini, L.; Heintz, R.T.; Hoffman, W.F.; and Casey, D.E. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics: A controlled study. Archives of General Psychiatry, 48:259-263, 1991.
40. Giorguieff-Chesselet, M.F.; Kernel, M.L.; Wandscheer, D.; and Glowinski, J. Regulation of dopamine release by presynaptic nicotine receptors on rat striatal slices: Effect of nicotine in a low concentration. Life Sciences, 25:1257-1262, 1979.
41. Glassman, A.H. Cigarette smoking: Implications for psychiatric illness. American Journal of Psychiatry, 150:546-553, 1993.
42. Glazer, W.M.; Morgenstern, H.; and Doucette, J. Race and tardive dyskinesia among outpatients at a CMHC. Hospital and Community Psychiatry, 45(1):38-42, 1994.
43. Goff, D.C.; Henderson, D.C.; and Amico, E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. American Journal of Psychiatry, 149:1189-1194, 1992.
44. Goldberg, T.E.; Berman, K.F.; and Weinberger, D.R. Neuropsychology and neurophysiology of schizophrenia. Current Opinion in Psychiatry, 8:34-40, 1995.
45. Goldberg, T.E., and Weinberger, D.R. The effects of clozapine on neurocognition: An overview. Journal of Clinical Psychiatry, 55:88-90, 1994.
46. Gulbinat, W.; Dupont, A.; Jablensky, A.; Jensen, O.M.; Marsella, A.; Nakane, Y.; and Sartorius, N. Cancer incidence of schizophrenic patients: Results of record linkage studies in three countries. British Journal of Psychiatry, 161:75-33, 1992.
47. Hamilton, M. Development of a rating scale for primary depressive illness. British Journal of Social Clinical Psychology, 6:278-296, 1967.
48. Harris, A.E. Physical disease and schizophrenia. Schizophrenia Bulletin, 14(1):85-96, 1988.
49. Heaton, R.K., and Drexler, M. Clinical neuropsychological findings in schizophrenia and aging. In: Miller, N.E., and Cohen, G.D., eds. Schizophrenia & Aging. New York, NY: Guilford Press, 1987. pp. 145-161.
50. Heaton, R.K.; Paulsen, J.S.; McAdams, L.A.; Kuck, J.; Zisook, S.; Braff, D.; Harris, M.J.; and Jeste, D.V. Neuropsychological deficits in schizophrenia: Relationship to age, chronicity and dementia. Archives of General Psychiatry, 51(6):469-476, 1994.
51. Houston, F., and Royce, A.B. Relationship between deafness and psychotic illness. Journal of Mental Science, 100:990-993, 1954.
52. Hughes, J.R.; Hatsukami, D.K.; Mitchell, J.E.; and Dahlgren, L.A. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143:993-997, 1986.
53. Hyde, T.M.; Nawroz, S.; Goldberg, T.E.; Bigelow, L.B.; Strong, D.; Weinberger, D.R.; and Kleinman, J.E. Is there cognitive decline in schizophrenia? A cross-sectional study. British Journal of Psychiatry, 164:494-500, 1994.
54. Imperato, A.; Mulas, A.; and Di Chiara, G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. European Journal of Pharmacology, 132:337-338, 1986.
55. Jeste, D.V.; Caligiuri, M.P.; Paulsen, J.S.; Heaton, R.K.; Lacro, J.P.; Harris, M.J.; Bailey, A.; Fell, R.L.; and McAdams, L.A. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients. Archives of General Psychiatry, 52:756-765, 1995a.
56. Jeste, D.V.; Eastham, J.H.; Lacro, J.P.; Gierz, M.; Field, M.G.; and Harris, M.J. Management of late-life psychosis. Journal of Clinical Psychiatry, in press.
57. Jeste, D.V.; Gierz, M.; and Harris, M.J. Pseudodementia: Myths and reality. Psychiatric Annals, 20:71-79, 1990.
58. Jeste, D. V.; Harris, M.J.; Krull, A.; Kuck, J.; McAdams, L.A.; and Heaton, R.K. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. American Journal of Psychiatry, 152:722-730, 1995b.
59. Jos, C.J.; Evenson, R.C.; and Mallya, A.R. Self-induced water intoxication: A comparison of 34 cases with matched controls. Journal of Clinical Psychiatry, 47:368-370, 1986.
60. Kane, J.M.; Jeste, D.V.; Barnes, T.R.E.; Casey, D.E.; Cole, J.O.; Davis, J.M.; Gualtieri, C.T.; Schooler, N.R.; Sprague, R.L.; and Wettstein, R.M. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association, Washington, DC: American Psychiatric Association, 1992.
61. Kane, J.M.; Woerner, M.; and Lieberman, J. Tardive dyskinesia: Prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology, 8(4):52S-56S, 1988.
62. Kane, J.M.; Woerner, M.G.; Pollack, S.; Safferman, A.Z.; and Lieberman, J.A. Does clozapine cause tardive dyskinesia? Journal of Clinical Psychiatry, 54:327-330, 1993.
63. Kay, D.W.K., and Roth, M. Physical accompaniments of mental disorder in old age. Lancet, 269:740-745, 1955.
64. Kay, D.W.K., and Roth, M. Environmental and hereditary factors in the schizophrenias of old age ("late paraphrenia") and their bearing on the general problem of causation in schizophrenia. Journal of Mental Science, 107:649-686, 1961.
65. Kirch, D.G.; Bigelow, L.B.; Weinberger, D.R.; Lawson, W.B.; and Wyatt, R.J. Polydipsia and chronic hyponatremia in schizophrenic inpatients. Journal of Clinical Psychiatry, 46:179-181, 1985.
66. Koczapski, A.B.; Ledwidge, B.; Paredes, J.; Kogan, C.; and Higenbottam, J. Multisubstance intoxication among schizophrenic inpatients: Reply to Hyde. Schizophrenia Bulletin, 16(3):373-375, 1990.
67. Koran, L.M.; Sox, H.C.; Marton, K.I.; Moltzen, S.; Sox, C.H.; Kraemer, H.C.; Imai, K.; Kelsey, T.G.; Rose, T.G.; Levin, L.C.; and Chandra, S. Medical evaluation of psychiatric patients. Archives of General Psychiatry, 46:733-740, 1989.
68. Koranyi, E.K. Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Archives of General Psychiatry, 36:414-419, 1979.
69. Kovar, M.G. Health of the elderly and use of health services. Public Health Reports, 92(Jan.-Feb.):9-19, 1977.
70. Kraepelin, E. Dementia Praecox and Paraphrenia. (1919) Translated by R.M. Barclay. Huntington, NY: Robert E. Krieger Publishing Company, 1971.
71. Kreeger, J.L.; Raulin, M.L.; Grace, J.; and Priest, B.L. Effect of hearing enhancement on mental status ratings in geriatric psychiatric patients. American Journal of Psychiatry, 152:629-631, 1995.
72. Kushnir, M.; Schattner, A.; Ezri, T.; and Konichezky, S. Schizophrenia and fatal self-induced water intoxication with appropriately diluted urine American Journal of the Medical Sciences, 300:385-387, 1990.
73. Lacro, J.P.; and Jeste, D.V. Physical comorbidity and polypharmacy in older psychiatric patients. Biological Psychiatry, 36:146-152, 1994.
74. Manschreck, T.C.; Keuthen, N.J.; Schneyer, M.L.; Celada, M.T.; Laughery, J.; and Collins, P. Abnormal involuntary movements and chronic schizophrenic disorders. Biological Psychiatry, 27:150-158, 1990.
75. Masterson, E., and O'Shea, B. Smoking and malignancy in schizophrenia. British Journal of Psychiatry, 145:429-432, 1984.
76. Mattis, A. Mental status examination for organic mental syndrome in the elderly patients. In: Bellak, L., and Karasu, T.B., eds. Geriatric Psychiatry. New York, NY: Grune & Stratton, 1976. pp. 77-122.
77. Mayfield, D.; McLeod, G.; and Hall, P. The CAGE questionnaire: Validation of a new alcoholism screening instrument. American Journal of Psychiatry, 131:1121-1123, 1974.
78. McKee, H.A.; D'Arcy, P.F.; and Wilson, P.J.K. Diabetes and schizophrenia - A preliminary study. Journal of Clinical and Hospital Pharmacy, 11:297-299, 1986.
79. Menza, M.A.; Grossman, N.; Van Horn, M.; Cody, R.; and Forman, N. Smoking and movement disorders in psychiatric patients. Biological Psychiatry, 30:109-115, 1991.
80. Mhoon, E. Otology. In: Cassel, C.K.; Riesenberg, D.E.; Sorensen, L.B.; and Walsh, J.R., eds. Geriatric Medicine. New York, NY: Springer-Verlag, 1990. pp. 403-419.
81. Miller, M.D.; Paradis, C.F.; Houck, P.R.; Mazumdar, S.; Stack, J.A.; Rifai, A.H.; Mulsant, B.; and Reynolds, C.F.I. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale (CIRS). Psychiatry Research, 41:237-248, 1992.
82. Mortensen, P.B. The incidence of cancer in schizophrenic patients. Journal of Epidemiology and Community Health, 43:43-47, 1989.
83. Mortensen, P.B. Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatrica Scandinavica, 85:390-393, 1992.
84. Mortensen, P.B., and Juel, K. Mortality and causes of death of schizophrenic patients in Denmark. Acta Psychiatrica Scandinavica, 81:372-377, 1990.
85. Mueser, K.T.; Bellack, A.S.; and Blanchard, J.J. Comorbidity of schizophrenia and substance abuse: Implications for treatment. Journal of Consulting and Clinical Psychology, 60:845-856, 1992.
86. Mueser, K.T.; Bellack, A.S.; Morrison, R.L.; and Wixted, J.T. Social competence in schizophrenia: Premorbid adjustment, social skill, and domains of functioning. Journal of Psychiatric Research, 24:51-63, 1990.
87. Mukherjee, S.; Rosen, A.M.; Caracci, G.; and Shukla, S. Persistent tardive dyskinesia in bipolar patients. Archives of General Psychiatry, 43:342-346, 1986.
88. Mukherjee, S.; Roth, S.D.; Sandyk, R.; and Schnur, D.B. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Research, 29:17-27, 1989a.
89. Mukherjee, S.; Schnur, D.B.; and Reddy, R. Family history of type 2 diabetes in schizophrenic patients. [Letter] Lancet, 1:495, 1989b.
90. Negrete, J.C.; Knapp, W.P.; Douglas, D.E.; and Smith, W.B. Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychological Medicine, 16:515-520, 1986.
91. New Encyclopedia Britannica. Vol. 6, 15th ed. Chicago, IL: Encyclopedia Britannica, Inc., 1993. p. 667.
92. Nissen, H.A., and Spencer, K.A. The psychogenic problem (endocrinal and metabolic) in chronic arthritis. New England Journal of Medicine, 21:567-581, 1936.
93. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
94. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacology Bulletin, 24(1):97-99, 1988.
95. Parmelee, P.A.; Thuras, P.D.; Katz, I.R.; and Lawton, M.P. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. Journal of the American Geriatrics Society, 43:130-137, 1995.
96. Patt, R.B.; Proper, G.; and Reddy, S. The neuroleptics as adjuvant analgesics. Journal of Pain and Symptom Management, 9:446-453, 1994.
97. Paulsen, J.S.; Romero, R.; Chan, A.; Davis, A.V.; Heaton, R.K.; and Jeste, D.V. Impairment of the semantic network in schizophrenia. Psychiatry Research, in press.
98. Paulsen, J.S.; Heaton, R.K.; Sadek, J.R.; Perry, W.; Delis, D.C.; Kuck, J.; Zisook, S.; Braff, D.; and Jeste, D.V. The nature of learning and memory impairments in schizophrenia. Journal of the International Neuropsychological Society, 1:88-99, 1995.
99. Prager, S., and Jeste, D.V. Sensory impairment in late-life schizophrenia. Schizophrenia Bulletin, 19(4):755-772, 1993.
100. Prohovnik, I.; Dwork, A.J.; Kaufman, M.A.; and Willson, N. Alzheimertype neuropathology in elderly schizophrenia patients. Schizophrenia Bulletin, 19(4):805-816, 1993.
101. Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.J.; Judd, L.L.; and Goodwin, F.K. Co-morbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiological Catchment Area (ECA) study. Journal of the American Medical Association, 264:2511-2518, 1990.
102. Rich, L.F. Ophthalmology. In: Cassel, C.K.; Riesenberg, D.E.; Sorensen, L.B.; and Walsh, J.R., eds. Geriatric Medicine. New York; NY: Springer-Verlag, 1990. pp. 394-404.
103. Saykin, A.J.; Gur, R.C.; Gur, R.E.; Mozley, P.D.; Mozley, L.H.; Resnick, S.M.; Kester, B.; and Stafiniak, P. Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Archives of General Psychiatry, 48:618-624, 1991.
104. Schneier, F.R., and Siris, S.G. A review of psychoactive substance use and abuse in schizophrenia: Patterns of drug choice. Journal of Nervous and Mental Disease, 175:641-652, 1987.
105. Schulberg, H.C.; McClelland, M.; and Burns, B.J. Depression and physical illness: The prevalence, causation, and diagnosis of comorbidity. Clinical Psychology Review, 7:145-167, 1987.
106. Selzer, M.L. The Michigan Alcoholism Screening Test: The quest for a new diagnostic instrument. American Journal of Psychiatry, 127:1653-1658, 1971.
107. Sheline, Y.I. High prevalence of physical illness in a geriatric psychiatric inpatient population. General Hospital Psychiatry, 12:396-400, 1990.
108. Skinner, H.A. The Drug Abuse Screening Test. Addictive Behaviors, 7:363-371, 1982.
109. Sorensen, L.B. Rheumatology. In: Cassel, C.K.; Riesenberg, D.E.; Sorensen, L.B.; and Walsh, J.R., eds. Geriatric Medicine. 2nd edition. New York, NY: Springer-Verlag, 1990. p. 200.
110. Spohn, H.E., and Strauss, M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98:367-380, 1989.
111. Stedman, T.L. Stedman's Medical Dictionary. 25th ed. Baltimore, MD: Williams & Wilkins Company, 1990.
112. Tsuang, M.T.; Perkins, K.; and Simpson, J.C. Physical diseases in schizophrenia and affective disorder. Journal of Clinical Psychiatry, 44:42-46, 1983.
113. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. Vital statistics of the United States, 1990. In: Mortality. Part A, Section 1, Vol. 2. Hyattsville, MD: National Center for Health Statistics, 1994. pp. 7-9.
114. Vinogradov, S.; Gottesman, I.I.; Moises, H.W.; and Nicol, S. Negative association between schizophrenia and rheumatoid arthritis. Schizophrenia Bulletin, 17(4):669-678, 1991.
115. Weiden, P.J.; Dixon, L.; Frances, A.; Appelbaum, P.; Haas, G.; and Rapkin, B. Neuroleptic noncompliance in schizophrenia. In: Tamminga, C., and Schulz, C., eds. Advances in Neuropsychiatry and Psychopharmacology. New York, NY: Raven Press, 1991. pp. 285-296.
116. Weiden, P.J.; Mott, T.; and Curcio, N. Recognition and management of neuroleptic noncompliance. In: Shriqui, C.L., and Nasrallah, H.A., eds. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press, 1995. pp. 463-486.
117. Yassa, R., and Jeste, D.V. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophrenia Bulletin, 18(4)701-715, 1992.
118. Yassa, R.; Lal, S.; Korpassy, A.; and Ally, J. Nicotine exposure and tardive dyskinesia. Biological Psychiatry, 22:67-72, 1987.
119. Zisook, S.; Heaton, R.; Moranville, J.; Kuck, J.; Jernigan, T.; and Braff, D. Past substance abuse and clinical course of schizophrenia. American Journal of Psychiatry, 149:552-553, 1992.